Cited by 1,217Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 159 of the 161 references it cites were found in a registry or an index.

Alzheimer’s disease: Clinical trials and drug development

Mangialasche, Francesca, Solomon, Alina, Winblad, Bengt, Mecocci, Patrizia, Kivipelto, Miia·2010·The Lancet Neurology

DOI 10.1016/s1474-4422(10)70119-8

Open this paper in CoChat — free account

Abstract

Alzheimer's disease is the most common cause of dementia in elderly people. Research into Alzheimer's disease therapy has been at least partly successful in terms of developing symptomatic treatments, but has also had several failures in terms of developing disease-modifying therapies. These successes and failures have led to debate about the potential deficiencies in our understanding of the pathogenesis of Alzheimer's disease and potential pitfalls in diagnosis, choice of therapeutic targets, development of drug candidates, and design of clinical trials. Many clinical and experimental studies are ongoing, but we need to acknowledge that a single cure for Alzheimer's disease is unlikely to be found and that the approach to drug development for this disorder needs to be reconsidered. Preclinical research is constantly providing us with new information on pieces of the complex Alzheimer's disease puzzle, and an analysis of this information might reveal patterns of pharmacological interactions instead of single potential drug targets. Several promising randomised controlled trials are ongoing, and the increased collaboration between pharmaceutical companies, basic researchers, and clinical researchers has the potential to bring us closer to developing an optimum pharmaceutical approach for the treatment of Alzheimer's disease.

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(10)70119-8

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Alzheimer’s disease
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention: Systematic Review and Meta-analysis
Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560
Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil: A Randomized Controlled Trial
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050
Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease
Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034
Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer’s disease
Reddy, P. H., & Beal, M. F. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.002 · Cited by 975
Brain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
The neuropathology of probable Alzheimer disease and mild cognitive impairment
Schneider, J. A., Arvanitakis, Z., Leurgans, S. E., & Bennett, D. A. (2009) · Annals of Neurology · doi:10.1002/ana.21706 · Cited by 935
The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal
Hardy, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06181.x · Cited by 814
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
ω-3 Fatty Acid Treatment in 174 Patients With Mild to Moderate Alzheimer Disease: OmegAD Study: A Randomized Double-blind Trial
Freund-Levi, Y., Eriksdotter-Jönhagen, M., Cederholm, T., Basun, H., Faxén-Irving, G., Garlind, A., Vedin, I., Vessby, B., Wahlund, L.-O., & Palmblad, J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1402 · Cited by 751
Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70167-4 · Cited by 725
The amyloid β-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae
Hansson Petersen, C. A., Alikhani, N., Behbahani, H., Wiehager, B., Pavlov, P. F., Alafuzoff, I., Leinonen, V., Ito, A., Winblad, B., Glaser, E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806192105 · Cited by 693
Self-citation
Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aβ
Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu, X., Smith, J. P., Perez, K., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.018 · Cited by 672
Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>
Green, R. C. (2009) · JAMA · doi:10.1001/jama.2009.1866 · Cited by 643
The worldwide societal costs of dementia: Estimates for 2009
Wimo, A., Winblad, B. G., & Jönsson, L. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.01.010 · Cited by 628
Self-citation
Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease
Fox, N. C., Black, R. S., Gilman, S., Rossor, M. N., Griffith, S. G., Jenkins, L., & Koller, M. (2005) · Neurology · doi:10.1212/01.wnl.0000159743.08996.99 · Cited by 550
The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia: Two Roads Converged
Craft, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.27 · Cited by 547
Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.
Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., & Harrington, C. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.11213 · Cited by 547
Alzheimer's disease – do tauists and baptists finally shake hands?
Mudher, A. K., & Lovestone, S. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02031-2 · Cited by 523
Intracerebroventricular Infusion of Nerve Growth Factor in Three Patients with Alzheimer’s Disease
Jönhagen, M. E., Nordberg, A. K., Amberla, K., Bäckman, L., Ebendal, T., Meyerson, B. A., Olson, L., Seiger, Å., Shigeta, M., Theodorsson, E., et al. (1998) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017069 · Cited by 472
Self-citation
Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study
Doody, R. S., Si, G., Sano, M. C., Thomas, R. G., Aisen, P. S. S., Бачурин, С. О., Seely, L., & Hung, D. S.-Y. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61074-0 · Cited by 458
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438
Self-citation
Vitamin E for Alzheimer's dementia and mild cognitive impairment
Farina, N., Llewellyn, D. J., Isaac, M. G. E. K. N., & Tabet, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub5 · Cited by 425
The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study
Chiu, C.-C., Su, K., Cheng, T., Liu, H., Chang, C.-J., Dewey, M. E., Stewart, R. J., & Huang, S. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.05.015 · Cited by 423
Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau
Green, K. N., Steffan, J. S., Martinez-Coria, H., Sun, X., Schreiber, S. S., Thompson, L. M., & LaFerla, F. M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3203-08.2008 · Cited by 404
Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study
Winblad, B. G., Kilander, L., Eriksson, S., Minthon, L., Båtsman, S., Wetterholm, A.-L., Jansson-Blixt, C., & Haglund, A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68350-5 · Cited by 400
Self-citation
Reassessing the amyloid cascade hypothesis of Alzheimer's disease
Pimplikar, S. W. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.12.015 · Cited by 389
Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model
McLaurin, J., Kierstead, M. E., Brown, M. E., Hawkes, C. A., Lambermon, M. H. L., Phinney, A. L., Darabie, A. A., Cousins, J. E., French, J. E., Lan, M. F., et al. (2006) · Nature Medicine · doi:10.1038/nm1423 · Cited by 373
A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo
Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M. B., Gich, I., Agulló, J. M., Pérez, M., Avila, J., Guardia-Laguarta, C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.025 · Cited by 368
Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease
Sanchez-Mejia, R. O., Newman, J. W. I., Toh, S., Yu, G.-Q., Zhou, Y., Halabisky, B., Cissé, M., Scearce-Levie, K. A., Cheng, I. H.-J., Gan, L., et al. (2008) · Nature Neuroscience · doi:10.1038/nn.2213 · Cited by 362
Can Alzheimer disease be prevented by amyloid-β immunotherapy?
Lemere, C. A., & Masliah, E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.219 · Cited by 351
Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice
Etcheberrigaray, R., Tan, M., Dewachter, I., Kuipéri, C., der Auwera, I. V., Wera, S., Qiao, L., Bank, B., Nelson, T. J., Kozikowski, A. P., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403921101 · Cited by 347
Immunosenescence: what does it mean to health outcomes in older adults?
McElhaney, J. E., & Effros, R. B. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.05.023 · Cited by 340
Nerve growth factor affects11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (Case Report)
Olson, L., Nordberg, A. K., von Holst, H., Bäckman, L., Ebendal, T., Alafuzoff, I. I., Amberla, K., Hartvig, P., Herlitz, A., Lilja, A., et al. (1992) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02257624 · Cited by 323
Self-citation
A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system
Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., Yarasheski, K. E., Friedrich, S. W., DeMattos, R. B., May, P. C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21623 · Cited by 322
Intravenous immunoglobulins containing antibodies against -amyloid for the treatment of Alzheimer's disease
Dodel, R. C. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.033399 · Cited by 319
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Relkin, N. R., Szabo, P., Adamiak, B., Burgut, T., Monthé, C., Lent, R. W., Younkin, S. G., Younkin, L. H., Schiff, R. I., & Weksler, M. E. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.021 · Cited by 305
Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
Hampel, H. J., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., et al. (2009) · PubMed · Cited by 305
Lithium Trial in Alzheimer's Disease
Hampel, H. J., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., et al. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04606 · Cited by 297
Minocycline Attenuates Neuronal Cell Death and Improves Cognitive Impairment in Alzheimer's Disease Models
Choi, Y., Kim, H., Shin, K. Y., Kim, E., Kim, M., Kim, H.-S., Park, C. H., Jeong, Y. H., Yoo, J., Lee, J., et al. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301377 · Cited by 296
Development of tau aggregation inhibitors for alzheimer's disease
Bulic, B., Pickhardt, M., Schmidt, B., Mandelkow, E., Waldmann, H., & Mandelkow, E. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802621 · Cited by 286
Degradation of the Alzheimer Disease Amyloid β-Peptide by Metal-dependent Up-regulation of Metalloprotease Activity
White, A. R., Du, T., Laughton, K. M., Volitakis, I., Sharples, R. A., Xilinas, M. E., Hoke, D. E., Holsinger, R. M. D., Evin, G., Cherny, R. A., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602487200 · Cited by 284
PPARγ Agonists as Therapeutics for the Treatment of Alzheimer's Disease
Landreth, G. E., Jiang, Q., Mandrekar, S., & Heneka, M. T. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.003 · Cited by 283
Substrate-targeting γ-secretase modulators
Kukar, T. L., Ladd, T. B., Bann, M. A., Fraering, P. C., Narlawar, R., Maharvi, G. M., Healy, B., Chapman, R., Welzel, A. T., Price, R. W., et al. (2008) · Nature · doi:10.1038/nature07055 · Cited by 279
Cellular prion protein regulates β-secretase cleavage of the Alzheimer's amyloid precursor protein
Parkin, E. T., Watt, N. T., Hussain, I., Eckman, E. A., Eckman, C. B., Manson, J. C., Baybutt, H. N., Turner, A. J., & Hooper, N. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609621104 · Cited by 274
Methylene Blue Delays Cellular Senescence and Enhances Key Mitochondrial Biochemical Pathways
Atamna, H., Nguyen, A., Schultz, C., Boyle, K., Newberry, J., Kato, H., & Ames, B. N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9610com · Cited by 272
Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders
Vellas, B. J., Black, R. S., Thal, L. J., Fox, N. C., Daniels, M., McLennan, G., Tompkins, C., Leibman, C. W., Pomfret, M., & Grundman, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509787602852 · Cited by 261
Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials
Winblad, B. G., Jones, R. W., Wirth, Y., Stöffler, A., & Möbius, H. J. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000102568 · Cited by 257
Self-citation
Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests
Bates, K. A., Verdile, G., Li, Q.-X., Ames, D., Hudson, P., Masters, C. L., & Martins, R. N. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.96 · Cited by 247
Long-term course and effectiveness of combination therapy in Alzheimer disease
Atri, A., Shaughnessy, L. W., Locascio, J. J., & Growdon, J. H. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31816653bc · Cited by 230
AddNeuroMed—The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease
Lovestone, S., Francis, P. T., Kłoszewska, I., Mecocci, P., Simmons, A., Soininen, H. S., Spenger, C., Tsolaki, M., Vellas, B. J., Wahlund, L., et al. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05064.x · Cited by 211
Self-citation
Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: Relevance to Alzheimer's disease
Opii, W. O., Joshi, G., Head, E., Milgram, N. W., Muggenburg, B. A., Klein, J. B., Pierce, W. M., Cotman, C. W., & Butterfield, D. A. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.09.012 · Cited by 202
A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease
Aisen, P. S. S., Saumier, D., Briand, R., Laurin, J., Gervais, F., Tremblay, P., & Garceau, D. (2006) · Neurology · doi:10.1212/01.wnl.0000244346.08950.64 · Cited by 198
Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms
Freund‐Levi, Y., Basun, H., Cederholm, T., Irving, G. F., Garlind, A., Grut, M., Vedin, I., Palmblad, J. E. W., Wahlund, L., & Eriksdotter, M. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1857 · Cited by 182
Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice
Muhs, A., Hickman, D. T., Pihlgren, M., Chuard, N., Giriens, V., Meerschman, C., der Auwera, I. V., LEUVEN, F. V., Sugawara, M., Weingertner, M.-C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703137104 · Cited by 182
Novel Neuroprotective Mechanisms of Memantine: Increase in Neurotrophic Factor Release from Astroglia and Anti-Inflammation by Preventing Microglial Activation
Wu, H.-M., Tzeng, N., Li, Q., Wei, S., Hu, X., Chen, S., Rawls, S. M., Flood, P. M., Hong, J., & Lu, R. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.64 · Cited by 174
Cell Signaling Pathways and Iron Chelation in the Neurorestorative Activity of Green Tea Polyphenols: Special Reference to Epigallocatechin Gallate (EGCG)
Mandel, S. A., Amit, T., Kalfon, L., Reznichenko, L., Weinreb, O., & Youdim, M. B. H. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15207 · Cited by 173
Mitochondria as a Target for Neurotoxins and Neuroprotective Agents
Бачурин, С. О., Shevtsova, E. F., Kireeva, E. G., Oxenkrug, G. F., & Sablin, S. O. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07541.x · Cited by 169
Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease
Henley, D. B., May, P. C., Dean, R. A., & Siemers, E. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903044982 · Cited by 168
Generation of Aβ38 and Aβ42 Is Independently and Differentially Affected by Familial Alzheimer Disease-associated Presenilin Mutations and γ-Secretase Modulation
Page, R. M., Baumann, K., Tomioka, M., Pérez‐Revuelta, B. I., Fukumori, A., Jacobsen, H., Flohr, A., Luebbers, T., Ozmen, L., Steiner, H., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m708754200 · Cited by 165
Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage
Matsuoka, Y., Gray, A. J., Hirata‐Fukae, C., Minami, S., Waterhouse, E. G., Mattson, M. P., LaFerla, F. M., Gozes, I., & Aisen, P. S. S. (2007) · Journal of Molecular Neuroscience · doi:10.1385/jmn/31:02:165 · Cited by 164
Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing
Marcade, M., Bourdin, J., Loiseau, N., Peillon, H., Rayer, A., Drouin, D., Schweighoffer, F., & Désiré, L. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05396.x · Cited by 155
Secretase inhibitors and modulators for Alzheimer’s disease treatment
Tomita, T. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.24 · Cited by 148
Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis
Wang, B.-S., Wang, H., Wei, Z.-H., Song, Y., Zhang, L., & Chen, H. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0189-x · Cited by 148
Current and future therapy in Alzheimer’s disease
van Marum, R. J. (2008) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00578.x · Cited by 146
Current Alzheimer's disease clinical trials: Methods and placebo outcomes
Schneider, L. S. S., & Sano, M. C. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.07.038 · Cited by 137
Mechanisms Behind the Neuroprotective Actions of Cholinesterase Inhibitors in Alzheimer Disease
Nordberg, A. K. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213804.59187.2d · Cited by 134
Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine
Wenk, G. L., Parsons, C. G., & Danysz, W. (2006) · Behavioural Pharmacology · doi:10.1097/00008877-200609000-00007 · Cited by 134
Vitamin E for Alzheimer's disease and mild cognitive impairment
Isaac, M. G. E. K. N., Quinn, R., & Tabet, N. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub2 · Cited by 134
Alzheimer's disease: new approaches to drug discovery
Bolognesi, M. L., Matera, R., Minarini, A., Rosini, M., & Melchiorre, C. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.04.619 · Cited by 132
Development of AFFITOPE vaccines for Alzheimer's disease (AD) — From concept to clinical testing
Schneeberger, A., Mandler, M., Otava, O., Zauner, W., Mattner, F., & Schmidt, W. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0070-5 · Cited by 130
Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease
Noble, W., Garwood, C., Stephenson, J., Kinsey, A. M., Hanger, D., & Anderton, B. (2009) · The FASEB Journal · doi:10.1096/fj.08-113795 · Cited by 123
Hope in Alzheimer's fight emerges from unexpected places
Gura, T. (2008) · Nature Medicine · doi:10.1038/nm0908-894 · Cited by 123
Amyloid β-Peptide Promotes Permeability Transition Pore in Brain Mitochondria
Moreira, P. I., Santos, M. S., Moreno, A. J., & Oliveira, C. R. (2001) · Bioscience Reports · doi:10.1023/a:1015536808304 · Cited by 122
NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model
Shiryaev, N., Jouroukhin, Y., Giladi, E., Polyzoidou, E., Grigoriadis, N., Rosenmann, H., & Gozes, I. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.02.011 · Cited by 122
Memoquin: A Multi-Target–Directed Ligand as an Innovative Therapeutic Opportunity for Alzheimer's Disease
Bolognesi, M. L., Cavalli, A., & Melchiorre, C. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.042 · Cited by 117
Double-Blind, Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimers Disease
Maher‐Edwards, G., Zvartau-Hind, M. E., Hunter, A. J., Gold, M., Hopton, G., Jacobs, G., Davy, M., & Williams, P. M. (2010) · Current Alzheimer Research · doi:10.2174/156720510791383831 · Cited by 117
Evaluation of Dimebon in cellular model of Huntington's disease
Wu, J., Li, Q., & Борисович, Б. И. (2008) · Molecular Neurodegeneration · doi:10.1186/1750-1326-3-15 · Cited by 117
Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies
Sigurdsson, E. M. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15202 · Cited by 116
Treatment with the selective muscarinic ml agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42in patients with Alzheimer's disease
Höck, C., Maddalena, A. S., Raschig, A., Müller-Spahn, F., Eschweiler, G. W., Huger, K., Hewer, I., Hampel, H. J., Müller-Thornsen, T., Oertel, W. H., et al. (2003) · Amyloid · doi:10.3109/13506120308995249 · Cited by 110
Multifunctional Neuroprotective Derivatives of Rasagiline as Anti-Alzheimer's Disease Drugs
Weinreb, O., Mandel, S. A., Bar‐Am, O., Yogev‐Falach, M., Avramovich‐Tirosh, Y., Amit, T., & Youdim, M. B. H. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.030 · Cited by 110
Delineating the Mechanism of Alzheimer’s Disease Aβ Peptide Neurotoxicity
Cappai, R., & Barnham, K. J. (2008) · Neurochemical Research · doi:10.1007/s11064-007-9469-8 · Cited by 108
Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: Relevance of Transgenic Mouse Studies to Clinical Trials
Wilcock, D. M., & Colton, C. A. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15404 · Cited by 107
Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease
Pilotto, A., Franceschi, M., D’Onofrio, G., Bizzarro, A., Mangialasche, F., Cascavilla, L., Paris, F., Matera, M. G., Pilotto, A., Daniele, A., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b6bbe3 · Cited by 107
Self-citation
Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine
Deiana, S., Harrington, C. R., Wischik, C. M., & Riedel, G. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1394-2 · Cited by 106
Effects of Omega-3 Fatty Acids on Inflammatory Markers in Cerebrospinal Fluid and Plasma in Alzheimer’s Disease: The OmegAD Study
Freund‐Levi, Y., Hjorth, E., Lindberg, C., Cederholm, T., Irving, G. F., Vedin, I., Palmblad, J. E. W., Wahlund, L., Schultzberg, M., Basun, H., et al. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000218081 · Cited by 104
Huperzine A protects isolated rat brain mitochondria against β-amyloid peptide
Gao, X., Zheng, C. Y., Yang, L., Tang, X. C., & Zhang, H. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.02.028 · Cited by 103
Pharmacological comparison of muscarinic ligands: Historical versus more recent muscarinic M1-preferring receptor agonists
Heinrich, J. N., Butera, J. A., Carrick, T. A., Kramer, A., Kowal, D. M., Lock, T., Marquis, K. L., Pausch, M. H., Popiolek, M., Sun, S.-C., et al. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.12.044 · Cited by 101
Site-specific UBITh® amyloid-β vaccine for immunotherapy of Alzheimer's disease
Wang, C. Y., Finstad, C. L., Walfield, A. M., Sia, C., Sokoll, K. K., Chang, T.-Y., Fang, X. D., Hung, C. H., Hutter-Paier, B., & Windisch, M. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.031 · Cited by 98
Towards Non Invasive Nerve Growth Factor Therapies for Alzheimer's Disease
Cattaneo, A., Capsoni, S., & Paoletti, F. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15210 · Cited by 96
CHF5074, a novel γ‐secretase modulator, attenuates brain β‐amyloid pathology and learning deficit in a mouse model of Alzheimer's disease
Imbimbo, B. P., Hutter‐Paier, B., Villetti, G., Facchinetti, F., Cenacchi, V., Volta, R., Lanzillotta, A., Pizzi, M., & Windisch, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00097.x · Cited by 87
Back to the future: the 'old-fashioned' way to new medications for neurodegeneration
Lansbury, P. T. (2004) · Nature Medicine · doi:10.1038/nrn1435 · Cited by 87
M1 Muscarinic Agonists Target Major Hallmarks of Alzheimer’s Disease – The Pivotal Role of Brain M1 Receptors
Fisher, A. (2008) · Neurodegenerative Diseases · doi:10.1159/000113712 · Cited by 87
Dimebon (Latrepirdine) Enhances Mitochondrial Function and Protects Neuronal Cells from Death
Zhang, S., Hedskog, L., Petersen, C. H., Winblad, B. G., & Ankarcrona, M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100174 · Cited by 85
Self-citation
Nogo receptor 1 regulates formation of lasting memories
Karlén, A., Karlsson, T. E., Mattsson, A., Lundströmer, K., Codeluppi, S., Pham, T. M., Bäckman, C. M., Ögren, S. O., Åberg, E., Hoffman, A. F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905390106 · Cited by 83
Why Did Tarenflurbil Fail in Alzheimer's Disease?
Imbimbo, B. P. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1092 · Cited by 75
Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI)
Dunbar, G. C., Inglis, F., Kuchibhatla, R., Sharma, T., Tomlinson, M., & Wamsley, J. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107066855 · Cited by 75
Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post‐hoc analyses of ADAS‐cog and SIB total and single‐item scores from six randomized, double‐blind, placebo‐controlled studies
Mecocci, P., Bladström, A., & Stender, K. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2226 · Cited by 72
Self-citation
Analysis of microdissected human neurons by a sensitive ELISA reveals a correlation between elevated intracellular concentrations of Aβ42 and Alzheimer’s disease neuropathology
Hashimoto, M., Bogdanovic, N., Volkmann, I., Aoki, M., Winblad, B., & Tjernberg, L. O. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0661-6 · Cited by 69
Self-citation
The Quest for Small Molecules as Amyloid Inhibiting Therapies for Alzheimer's Disease
Amijee, H., & Scopes, D. I. C. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1044 · Cited by 65
NAP and D-SAL: neuroprotection against the β amyloid peptide (1–42)
Gozes, I., Divinski, I., & Piltzer, I. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s3-s3 · Cited by 62
γ-Secretase: a complex target for Alzheimer's disease
Lundkvist, J., & Näslund, J. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.10.002 · Cited by 58
Phenserine
Klein, J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.7.1087 · Cited by 56
Alzheimers Disease Drug Development in 2008 and Beyond: Problems and Opportunities
Becker, R. E., & Greig, N. H. (2008) · Current Alzheimer Research · doi:10.2174/156720508785132299 · Cited by 55
Can Lithium or Valproate Untie Tangles in Alzheimer's Disease?
Tariot, P. N., & Aisen, P. S. S. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09com05331 · Cited by 53
Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets
Pei, J.-J., Sjögren, M., & Winblad, B. (2008) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328314b78b · Cited by 49
Self-citation
Immunotherapy against APP β-Secretase Cleavage Site Improves Cognitive Function and Reduces Neuroinflammation in Tg2576 Mice without a Significant Effect on Brain Aβ Levels
Rakover, I. S., Arbel, M., & Solomon, B. (2007) · Neurodegenerative Diseases · doi:10.1159/000103250 · Cited by 45
Amyloid‐beta reduction by memapsin 2 (beta‐secretase) immunization
Chang, W., Downs, D., Huang, X., Da, H., Fung, K.-M. A., & Tang, J. (2007) · The FASEB Journal · doi:10.1096/fj.06-7993com · Cited by 40
Review: Donepezil in Severe Alzheimer's Disease
Winblad, B. G. (2009) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317509332094 · Cited by 38
Self-citation
Cholesterol-modifying strategies for Alzheimer’s disease
Solomon, A., & Kivipelto, M. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.25 · Cited by 35
Self-citation
P4‐346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease
Siemers, E., Friedrich, S. W., Dean, R. A., Sethuraman, G., Demattos, R. B., Jennings, D. L., Tamagnan, G. D., MAREK, K. L., & Seibyl, J. P. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.2416 · Cited by 32
O2‐05‐05: Results of the first‐in‐man study with the active Aβ Immunotherapy CAD106 in Alzheimer patients
Winblad, B. G., Minthon, L., Floesser, A., Imbert, G., Dumortier, T., He, Y., Maguire, P., Karlsson, M., Östlund, H., Lundmark, J., et al. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.356 · Cited by 32
Self-citation
Alzheimer's disease: γ-secretase inhibitors
Imbimbo, B. P. (2008) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.10.002 · Cited by 32
Nogo Receptor Interacts with Brain APP and Aβ to Reduce Pathologic Changes in Alzheimers Transgenic Mice
Park, J. H., & Strittmatter, S. M. (2007) · Current Alzheimer Research · doi:10.2174/156720507783018235 · Cited by 30
Emerging and potential therapies for Alzheimer's disease
Jarosz-Griffiths, H., Morten, I. J., & Hooper, N. M. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.6.693 · Cited by 30
P2‐240: PF‐04447943, a novel PDE9A inhibitor, increases cGMP levels in cerebrospinal fluid: Translation from non‐clinical species to healthy human volunteers
Nicholas, T., Evans, R. M., Styren, S. D., Qiu, R., Wang, E. Q., Nelson, F., Le, V., Grimwood, S., Christoffersen, C. L., Banerjee, S., et al. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.553 · Cited by 25
Cortical Changes Following Spinal Cord Injury with Emphasis on the Nogo Signaling System
Endo, T., Tominaga, T., & Olson, L. (2009) · The Neuroscientist · doi:10.1177/1073858408329508 · Cited by 23
The Perils of Alzheimers Drug Development
Schneider, L. S. S., & Lahiri, D. K. (2009) · Current Alzheimer Research · doi:10.2174/156720509787313871 · Cited by 22
O2‐05‐03: Immunotherapy targeting abnormal protein conformation
Wısnıewskı, T., Prelli, F. C., Scholtzova, H., Chung, E., Mehta, P. D., Kascsak, R., Kascsak, R. J., & Goñi, F. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.354 · Cited by 20
O1‐04‐06: Effects of rosiglitazone as monotherapy in APOE4‐stratified subjects with mild‐to‐moderate Alzheimer's disease
Gold, M., Alderton, C., Zvartau-Hind, M. E., Ritchie, S. Y., Saunders, A. M., Craft, S., Landreth, G. E., Linnamägi, Ü., & Sawchak, S. T. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.219 · Cited by 18
P3‐254: Exebryl‐1: A novel small molecule currently in human clinical trials as a disease‐modifying drug for the treatment of Alzheimer's disease
Snow, A. D., Cummings, J. A., Lake, T. P., Hu, Q., Esposito, L., Cam, J. A., Hudson, M., Smith, E., & Runnels, S. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.925 · Cited by 18
P4‐348: Evp‐6124: Safety, Tolerability And Cognitive Effects Of A Novel A7 Nicotinic Receptor Agonist In Alzheimer's Disease Patients On Stable Donepezil Or Rivastigmine Therapy
Hilt, D. C., Gawryl, M. S., Koenig, G., & The EVP‐6124 Study Group (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.07.147 · Cited by 18
P1‐279: NIC5‐15 as a treatment for Alzheimer's: Safety, pharmacokinetics and clinical variables
Grossman, H. T., Marzloff, G. E., Luo, X., LeRoith, D., Sano, M. C., & Pasinetti, G. M. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.287 · Cited by 17
O1‐04‐03: The ADCS valproate neuroprotection trial: Primary efficacy and safety results
Tariot, P. N., Aisen, P. S. S., Cummings, J. L., Jakimovich, L. J., Schneider, L. S. S., Thomas, R. G., Becerra, L. M., & Loy, R. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.216 · Cited by 16
P4‐351: Effects of uninterrrupted intravenous immunoglobulin treatment of Alzheimer's disease for nine months
Tsakanikas, D., Shah, K., Flores, C., Assuras, S., & Relkin, N. R. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.2422 · Cited by 14
P1‐268: Clinical trials of EHT 0202, a neuroprotective and procognitive alpha‐secretase stimulator for Alzheimer's disease
Désiré, L., Marcade, M., Peillon, H., Drouin, D., Sol, O., & Pando, M. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.276 · Cited by 14
O1‐04‐02: A clinical trial of docosahexanoic acid (DHA) for the treatment of Alzheimer's disease
Quinn, J. F., Raman, R., Thomas, R. G., Ernstrom, K. B., Yurko‐Mauro, K., Nelson, E. B., Shinto, L. H., Nair, A. K., & Aisen, P. S. S. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.215 · Cited by 14
P2‐375: Efficacy of the novel γ‐secretase inhibitor, PF‐3084014, in reducing Aβ in brain, CSF, and plasma in guinea pigs and Tg2576 mice
Wood, K. M., Lanz, T. A., Coffman, K. J., Becker, S. L., Deusen, J. V., Nolan, C. E., Richter, K. E. G., Finley, J. E., Brown, T. M., Brodney, M. A., et al. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.1453 · Cited by 13
P2‐377: A phase 2, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and effect on cognitive function of AL‐108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment
Schmechel, D. E., Gerard, G., Vatakis, N. G., Harper, L., Ross, J., Bari, M. A., Walling, D. P., Stedman, M., Winston, J. L., Morimoto, B. H., et al. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.1455 · Cited by 13
O3‐06‐07: GSI‐953 is a potent APP‐selective gamma‐secretase inhibitor for the treatment of Alzheimer's disease
Jacobsen, S. J., Comery, T. A., Kreft, A. F., Mayer, S. C., Zaleska, M. M., Riddell, D. R., Bard, J., Gonzales, C., Frick, G. S., Raje, S., et al. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.472 · Cited by 12
O1‐04‐01: Results of the MIDAS trial: Effects of docosahexaenoic acid on physiological and safety parameters in age‐related cognitive decline
Yurko‐Mauro, K., McCarthy, D., Bailey‐Hall, E., Nelson, E. B., Blackwell, A. D., & MIDAS Investigators (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.214 · Cited by 10
F1‐01‐04: Beta‐secretase as target for amyloid‐reduction therapy
Tang, J. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.177 · Cited by 10
Evaluation of β‐Alanine‐ and GABA‐Substituted Peptides as Inhibitors of Disease‐Linked Protein Aggregation
Madine, J., Wang, X., Brown, D. R., & Middleton, D. A. (2009) · ChemBioChem · doi:10.1002/cbic.200900219 · Cited by 10
P2‐213: Oral amyloid anti‐aggregating agent ELND005 is measurable in CSF and brain of healthy adult men
Garzone, P. D., Koller, M., Pastrak, A., Jhee, S. S., Ereshefsky, L., Moran, S., Cedarbaum, J. M., Xu, V., & Ross, B. D. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.526 · Cited by 10
P3‐243: The role for CSF dynabridging studies in developing new therapies for Alzheimer's disease
Ereshefsky, L., Jhee, S. S., Yen, M., & Moran, S. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.1016 · Cited by 9
F1‐01‐02: Rember: Issues in design of a phase 3 disease modifying clinical trial of Tau aggregation inhibitor therapy in Alzheimer's disease
Wischik, C. M. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.175 · Cited by 9
Double-Blind, Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimer's Disease
Maher‐Edwards, G., Zvartau-Hind, M. E., Hunter, A. J., Gold, M., Hopton, G., Jacobs, G., Davy, M., & Williams, P. M. (2010) · Current Alzheimer Research · doi:10.2174/1567210200438162050 · Cited by 9
P1‐259: Aβ variability and effect of gamma secretase inhibition on cerebrospinal fluid levels of Aβ in healthy volunteers
Soares, H. D., Raha, N., Sikpi, M. O., Liston, D. R., Brodney, M., Coffman, K. J., Tate, B. A., Qiu, R., Wang, E. Q., Li, X., et al. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.267 · Cited by 8
O4‐04‐03: Safety and pharmacokinetics of the anti‐amyloid monoclonal antibody PF‐04360365 following a single infusion in patients with mild‐to‐moderate Alzheimer's disease: Preliminary results
Bednar, M. M., Zhao, Q., Landen, J. W., Billing, C. B., Rohrbacher, K. D., & Kupiec, J. W. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.542 · Cited by 7
P1‐266: Disease progression analysis of ADAS‐cog from ADNI database in normal elderly, mild cognitive impairment and Alzheimer's disease patients
Ito, K., Corrigan, B., Zhao, Q., French, J. L., Miller, R., & Fullerton, T. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.274 · Cited by 7
P1‐254: A safety, tolerability and pharmacokinetic study of dimebon in patients with Alzheimer's disease already receiving donepezil
Tariot, P. N., Sabbagh, M. N., Flitman, S. S., Reyes, P. F., Taber, L., & Seely, L. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.262 · Cited by 7
P2‐221: ABT‐089, a neuronal nicotinic receptor partial agonist, reverses scopolamine‐induced cognitive deficits in healthy normal subjects
Baker, J. D., Lenz, R. A., Locke, C. S., Wesnes, K. A., Maruff, P. T., Abi‐Saab, W., & Saltarelli, M. D. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.534 · Cited by 6
[P‐167]: The Development of NIC5‐15, a natural anti‐diabetic agent, in the treatment of Alzheimer's disease
Wang, J., Ho, L., & Pasinetti, G. M. (2005) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2005.06.228 · Cited by 6
P2‐238: Modulation of catecholaminergic and cholinergic neurons in mice fed with LMN diet, rich in polyphenols and polyunsaturated fatty acids
Bolea, I., Valente, T., Hidalgo, J., Comes, G., Ramírez, B., Anglés, M. N., Morelló, J. R., Reguant, J., Boada, M., & Unzeta, M. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.551 · Cited by 5
P1‐258: Prediction of treatment response to rivastigmine in Parkinson's Disease Dementia
Adler, G., Bektas, M., Ko-Inoshishi, Y., Tracik, F. M., & The RIVAPARK Study Group (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.266 · Cited by 4
P3‐242: The role of autophagy in potentially therapeutic copper complexes
Price, K. A., Lim, S. C., Patterson, B., Caragounis, A., Volitakis, I., Cherny, R. A., Masters, C. L., Barnham, K. J., Donnelly, P. S., Crouch, P. J., et al. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.1015 · Cited by 4
O1‐04‐04: A multicenter, double‐blind, placebo‐controlled phase IIb proof‐of‐concept dose‐ranging study of AZD3480 and donepezil over 12 weeks in patients with mild to moderate Alzheimer's disease
Frölich, L., Eckerwall, G., Jonas, N., & The Sirocco Investigators (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.217 · Cited by 4
Untitled work
(2000) · doi:10.1002/1531-8249(200012)48:6

Research works printed but not linked: 3

Solomon, 2010, A new target for Alzheimer's disease immunotherapy. 11th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2010, Geneva, Switzerland, Neurobiol Aging, 31, S29
Lenz R, Berry SM, Pritchett YL, et al. Novel investigation of a neuronal nicotinic receptor partial agonist in the treatment of Alzheimer's disease. 11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; Geneva, Switzerland; March 24–27, 2010. P100.
Eriksdotter, 2010, Therapy of Alzheimer's disease with NGF. 11th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2010, Geneva, Switzerland, Neurobiol Aging, 31, S9

Sorted by citations

Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188
ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease
Simpson, D. S. A., & Oliver, P. L. (2020) · Antioxidants · doi:10.3390/antiox9080743 · Cited by 1,044
Brain atrophy in Alzheimer’s Disease and aging
Pini, L., Pievani, M., Bocchetta, M., Altomare, D., Bosco, P., Cavedo, E., Galluzzi, S., Marizzoni, M., & Frisoni, G. B. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.002 · Cited by 836
A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808

See all 1,217

Authors: Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M.
Affiliations: University of Perugia (IT)
University of Eastern Finland (FI)
Karolinska Institutet (SE)
Corresponding author: Winblad, Bengt
ORCID: Mangialasche, Francesca
Solomon, Alina
Winblad, Bengt
Mecocci, Patrizia
Kivipelto, Miia
Venue: The Lancet Neurology
Publisher: Elsevier BV
Published: 2010-07
Volume: 9
Issue: 7
Pages: 702-716
ISSN: 1474-4422 (ISSN-L)
DOI: 10.1016/s1474-4422(10)70119-8
OpenAlex: W2129267808
Cited by: 1,217
References: 161
Citations by year: 2026: 31 · 2025: 47 · 2024: 53 · 2023: 45 · 2022: 91 · 2021: 80 · 2020: 69 · 2019: 77 · 2018: 82 · 2017: 79 · 2016: 78 · 2015: 89 · 2014: 121 · 2013: 97 · 2012: 80
FWCI: 8.96
Type: journal article
Language: en
Update notices: erratum (2011-06-01)
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords: Alzheimer's disease, drug development, clinical trials, disease-modifying therapy, symptomatic treatment, therapeutic target, pathogenesis, dementia, drug interactions, randomized controlled trials, translational research
MeSH terms: Alzheimer Disease, Clinical Trials as Topic, Humans, Antipsychotic Agents, Drug Design

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Alzheimer’s disease: Clinical trials and drug development

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks